RETA - Reata Pharmaceuticals, Inc.
| Previous Close | 23.87 |
| Open | 23.70 |
| Bid | 1.00 x 200 |
| Ask | 25.00 x 500 |
| Day's Range | 23.04 - 23.95 |
| 52 Week Range | 19.31 - 40.88 |
| Volume | 265,453 |
| Avg. Volume | 208,977 |
| Market Cap | 624.063M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.99 |
| Earnings Date | Aug 9, 2017 - Aug 14, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.71 |
- GlobeNewswire•9 days ago
Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome
Bardoxolone Treatment Produced Significant Increase in Kidney Function Maintained Through Week 36. Conference Call With Management Scheduled Thursday, April 12 th at 8:30am ET. IRVING, Texas, April 11, ...
- GlobeNewswire•18 days ago
Reata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology Conference
Novel, Orally-Bioavailable Agent With Potent Activity in Cell-Based and Animal Models. Non-Human Primate Proof-of-Concept for Suppression of IL-17A Achieved. Phase 1 Initiation for RTA 1701 Planned in ...
- GlobeNewswire•22 days ago
Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
IRVING, Texas, March 29, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that its licensee, Kyowa Hakko Kirin Co. Ltd., received designation under the Priority ...
- ACCESSWIRE•26 days ago
Wired News – Reata Pharma Reports Positive Top-line Data from its Phase-2 LARIAT Trial
Stock Monitor: Athersys Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 26, 2018 / Active-Investors.com has just released a free research report on Reata Pharmaceuticals, Inc. (NASDAQ: RETA ). ...
- GlobeNewswire•last month
Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial
Significant Improvement in 6 MWD in Patients With IPF and Sarcoidosis. IRVING, Texas, March 22, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced positive ...
- GlobeNewswire•last month
Report: Developing Opportunities within Super Micro Computer, Post, Reata Pharmaceuticals, Landstar System, Central Garden & Pet, and Albany International — Future Expectations, Projections Moving into 2018
NEW YORK, March 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- GlobeNewswire•last month
Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference
IRVING, Texas, March 16, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced that Chief Development Officer, Keith Ward, Ph.D., will present at the 15 th Annual ...
- GlobeNewswire•2 months ago
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2017 Financial and Operating Results
ADVANCED TWO PROGRAMS INTO PIVOTAL TRIALS IN 2017. CARDINAL PHASE 2 RETAINED BENEFIT DATA EXPECTED 3 Q18. DATA FROM FIRST PHOENIX COHORT EXPECTED 2 H18.
- GlobeNewswire•2 months ago
Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies
IRVING, Texas, March 01, 2018-- Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, today announced top-line data from the dose-escalation cohorts of the Phase 2 MOTOR trial of omaveloxolone ...
- GlobeNewswire•2 months ago
Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials
First patient enrolled for all cohorts of PHOENIX. First data from PHOENIX expected 2 H18. Retained benefit analysis from Phase 2 portion of CARDINAL expected 3 Q18.
- GlobeNewswire•2 months ago
Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial
Progressive loss of kidney function is a validated independent predictor of death and hospitalization in PAH patients. Increases in eGFR from bardoxolone methyl treatment were maintained for two years. ...
- Simply Wall St.•4 months ago
Who Owns Most Of Reata Pharmaceuticals Inc (NASDAQ:RETA)?
In this article, I’m going to take a look at Reata Pharmaceuticals Inc’s (NASDAQ:RETA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- Capital Cube•5 months ago
ETFs with exposure to Reata Pharmaceuticals, Inc. : November 30, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Reata Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to RETA-US. Comparing the performance and risk of Reata Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Zacks•5 months ago
Is a Surprise Coming for Reata Pharmaceuticals (RETA) This Earnings Season?
Reata Pharmaceuticals (RETA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- Capital Cube•6 months ago
Reata Pharmaceuticals, Inc. – Value Analysis (NASDAQ:RETA) : October 30, 2017
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Reata Pharmaceuticals, Inc. a score of 50. Our analysis is based on comparing Reata Pharmaceuticals, Inc. with the following peers – OrganiGram Holdings Inc, Ohr Pharmaceutical, Inc., Oragenics, Inc. and OncoCyte Corp. (OGI-CA, OHRP-US, OGEN-US and OCX-US). Investment Outlook Reata Pharmaceuticals, Inc. has a fundamental score of ... Read more (Read more...)
